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Doxorubicin (DOXO) induces significant, but transient, increases in apoptosis in the stem cell 26 
zone of the jejunum, followed by mucosal damage involving a decrease in crypt proliferation, 27 
crypt number, and villus height. The gastrointestinal tract is home to a vast population of 28 
commensal bacteria and numerous studies have demonstrated a symbiotic relationship 29 
between intestinal bacteria and intestinal epithelial cells (IEC) in maintaining homeostatic 30 
functions of the intestine. However, whether enteric bacteria play a role in DOXO-induced 31 
damage is not well understood. We hypothesized that enteric bacteria are necessary for 32 
induction of apoptosis and damage associated with DOXO treatment. Conventionally raised 33 
(CONV) and germ free (GF) mice were given a single injection of DOXO, and intestinal tissue 34 
was collected at 6, 72, and 120 h after treatment and from no treatment (0 h) controls. 35 
Histology and morphometric analyses quantified apoptosis, mitosis, crypt depth, villus height, 36 
and crypt density. Immunostaining for muc2 and lysozyme evaluated Paneth cells, goblet 37 
cells or dual stained intermediate cells. DOXO administration induced significant increases 38 
in apoptosis in jejunal epithelium regardless of the presence of enteric bacteria; however, the 39 
resulting injury, as demonstrated by statistically significant changes in crypt depth, crypt 40 
number, and proliferative cell number, was dependent upon the presence of enteric bacteria. 41 
Furthermore, we observed expansion of Paneth and goblet cells and presence of 42 
intermediate cells only in CONV and not GF mice. These findings provide evidence that 43 
manipulation and/or depletion of the enteric microbiota may have clinical significance in 44 
limiting chemotherapy-induced mucositis. 45 
  46 
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Introduction  47 
The small intestinal epithelium is one of the most rapidly proliferating tissues in the 48 
body. This property renders intestinal epithelial cells (IEC) particularly susceptible to 49 
chemotherapy-induced damage which is reported in up to 40% of patients who receive 50 
chemotherapy. 1 Chemotherapy-induced cytotoxicity within the gastrointestinal tract 51 
manifests as mucositis, characterized by gross ulcerations of the intestinal mucosa. The 52 
development of mucositis is a limiting factor in administration of chemotherapeutic agents, 53 
and therefore strategies to reduce this side-effect are urgently sought.  54 
Doxorubicin (DOXO) is a common chemotherapeutic utilized for sarcomas, select 55 
breast cancers, and several metastatic cancers. We previously reported that a single injection 56 
of DOXO given to mice induced significant, but transient, increases in apoptosis in the stem 57 
cell zone of the jejunum, followed by mucosal damage involving a decrease in crypt 58 
proliferation, crypt number, and villus height. 2 Subsequently, repair occurred, characterized 59 
by crypt hypertrophy, Paneth cell hyperplasia  and, ultimately, return of the intestinal mucosa 60 
to normal morphology. 3  61 
The gastrointestinal tract is home to a vast population of commensal bacteria and 62 
numerous studies have demonstrated the importance of the symbiotic relationship between 63 
intestinal bacteria and IECs in maintaining homeostatic functions of the intestine, including 64 
nutrient generation and metabolism and proper development of the innate immune system. 65 
4,5,6,7 Evidence in models of intestinal damage, indicate distinct effects of bacteria in different 66 
regions of the gastrointestinal tract. For example, in colon of mice that lack TLR signaling 67 
(MyD88-/-), restitution and repair following epithelial injury is impaired. 8 Similarly, germ free 68 
(GF) mice have shorter colonic crypts 9 and are more susceptible to chemical-induced injury, 69 
10 providing additional support for a role of commensal microbiota in sustaining epithelial 70 
integrity or promoting mucosal repair in the colon.  In contrast, in the small intestine, the 71 
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presence of enteric bacteria and/or bacterial products appears to exacerbate damage. For 72 
example, in both TLR4-/- and MyD88-/- mice, intestinal damage after exposure to 73 
indomethacin was abrogated. 11 Similarly, deficiency of TLR2 or TLR9 expression or inhibition 74 
of TLR9 activity were associated with significantly decreased DOXO-induced damage to the 75 
small intestine. 12 Additionally, the microbiota promotes  inflammation and fibrosis following 76 
small bowel resection, 13 reflective of the ‘double edged-sword’ role of intestinal microbiota 77 
associated-signaling in mucosal repair. These data led us to question whether enteric 78 
bacteria play a role in mucosal damage associated with chemotherapeutic agents like DOXO. 79 
In this report, we tested the hypothesis that enteric bacteria were necessary for 80 
induction of apoptosis and mucosal damage associated with DOXO treatment. Our data show 81 
that DOXO administration induces apoptosis regardless of the presence of enteric bacteria, 82 
but that the resulting damage, as demonstrated by changes in crypt depth, crypt number, and 83 
proliferative index, is enteric bacteria-dependent. These findings provide evidence that 84 
manipulation and/or depletion of the enteric microbiota may have clinical significance in 85 





DOXO treatment rapidly induced apoptosis in both GF and CONV small intestine. 89 
We previously reported that DOXO exposure rapidly induces apoptosis in crypt epithelium of 90 
CONV mice and that apoptosis peaked at 6h and remained elevated relative to control mice 91 
out to 120h after DOXO treatment. 2 In the current study, similar levels of apoptosis were 92 
observed in crypt epithelium of both GF and CONV mice, as assessed by both H&E staining 93 
and cleaved caspase 3 (Fig. 1A), at 6h following DOXO treatment. However, by 72h post 94 
DOXO treatment apoptosis had returned to baseline levels (Fig. 1B). Consistent with prior 95 
findings 2 cell positional analysis revealed that DOXO-induced apoptosis occurred primarily 96 
in cell positions 3-6, indicative of involvement of the intestinal stem cell zone (Fig. 1C). 97 
Although not significantly different from CONV, there may be an indication that apoptosis is 98 
occurring in cell positions higher up the crypt in GF, compared with CONV mice.  This may 99 
suggest that cells of different lineages and/or differentiation status are more susceptible to 100 
DOXO-induced apoptosis in GF vs. CONV mice, or that DOXO-induced apoptosis induces a 101 
higher turnover in GF mice. 102 
Alterations in villus-crypt morphometry in CONV, but not GF mice, following DOXO. 103 
  We previously demonstrated that an increase in crypt depth 120h following DOXO 104 
treatment was a hallmark of the repair phase and that villus blunting was evident at that time 105 
as well. 2 Though GF crypts were significantly shorter than CONV crypts at baseline, GF mice 106 
showed no significant change in crypt depth throughout the entire time course after DOXO 107 
treatment (Fig. 2A and B).  In contrast, by 120h after DOXO, crypts were significantly deeper 108 
in CONV mice compared to both control CONV mice and to GF mice at 120h after DOXO. 109 
GF mice showed no significant change in villus height throughout the entire time course after 110 
DOXO treatment (Fig. 2C). CONV mice, while not statistically different, demonstrated a trend 111 
toward shorter villi after DOXO treatment similar to our previous report. 2  112 
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  Our previous studies demonstrated a significant increase in proliferative index during 113 
repair following DOXO-induced damage which marked the movement of the intestinal 114 
mucosa in the repair phase. 2 Immunohistochemistry revealed a significant increase in the 115 
number pHH3+ cells in crypt epithelium of CONV mice at 120h following DOXO treatment, 116 
indicating an increase in crypt cell proliferation and this increase was not observed in GF 117 
mice (Fig. 3A and B). Similarly, we previously observed increases in the number of mitotic 118 
figures in crypt epithelium during repair. 2 Evaluation of the number of mitotic figures per crypt 119 
in both GF and CONV mice following DOXO revealed significantly decreased numbers in 120 
both GF and CONV crypts at 6h following DOXO, consistent with induction of DNA damage 121 
and cell cycle arrest (Fig. 3C).  The number of mitotic figures per crypt remained significantly 122 
decreased in CONV mice but returned to control levels in GF mice at 72h following DOXO. 123 
A return of mitotic figure number to control levels in CONV mice was observed by 120h 124 
following DOXO treatment. Of note, at baseline the number of mitotic figures per crypt was 125 
significantly greater in CONV compared to GF mice.  126 
 We previously demonstrated that DOXO-treatment of CONV mice resulted in significant 127 
crypt loss by 72h and this loss of crypts can be used as an indicator of loss of intestinal stem 128 
cells. 2 Although apoptosis and cell cycle arrest were observed in both GF and CONV crypt 129 
epithelium following DOXO treatment, only in CONV mice was this followed by significant 130 
loss of crypt number assessed by reduced crypt density. By 72h following DOXO treatment, 131 
crypt density was significantly decreased in CONV mice compared to control CONV mice, 132 
and compared to GF mice at 72h after treatment with DOXO (Fig. 4). This decrease in crypt 133 
density was still observed at 120 h after DOXO in CONV mice, but trended toward restitution 134 




Expansion of the Paneth cell compartment is absent in GF mice following DOXO 137 
treatment. 138 
We previously reported an expansion of the Paneth cell compartment in jejunal crypts 139 
following DOXO-induced damage in CONV mice which in turn increases the intestinal stem 140 
cell niche. 2 This expansion included an increase in total lysozyme-positive cell and 141 
intermediate cell (muc2 and lysozyme expressing cell) numbers suggesting alteration in 142 
secretory cell lineage allocation or maturation. 3 As Paneth cells play a critical role in sensing 143 
and responding to enteric bacteria 14 we wished to evaluated whether the absence of enteric 144 
bacteria in GF mice would alter the Paneth cell compartment. Following DOXO treatment, 145 
staining sections for lysozyme and muc2 revealed an expansion of lysozyme-positive cells at 146 
the crypt base 120 h after DOXO in CONV mice. In addition, staining revealed the presence 147 
of muc2- and lysozyme-expressing intermediate cells in CONV mice following DOXO 148 
treatment (Fig. 5). This is in contrast to the lack of expansion of lysozyme-positive cell 149 
numbers and presence of intermediate cells is observed in GF crypts following DOXO 150 




      This study demonstrates that enteric bacteria are necessary for the initiation and 153 
maintenance of mucosal damage and repair observed in the jejunum of CONV mice following 154 
DOXO treatment, which includes crypt loss and villus blunting, followed by an increase in 155 
proliferating cells, and crypt hyperplasia.  In contrast, enteric bacteria do not appear to be 156 
necessary for the rapid DOXO-mediated induction of apoptosis which was induced to similar 157 
levels in both GF and CONV raised mice, and in a similar cell position distribution.  Likewise, 158 
DOXO treatment results in a decreased number of mitotic figures in the crypt epithelium of 159 
both GF and CONV mice. Together, these data suggest that the damage-associated crypt 160 
loss and subsequent crypt regeneration documented in CONV mice is not secondary to the 161 
rapid induction of apoptosis observed in crypt epithelial cells following DOXO treatment; but, 162 
rather, is coupled to the presence of enteric bacteria. While DOXO is a widely used 163 
anticancer drug, its mechanism of action is not completely understood. Classically, DOXO is 164 
described as a topoisomerase II inhibitor and, as such, inhibits the re-ligation of cleaved DNA 165 
strands which have been unwound for transcription and replication. This inhibition results in 166 
DNA double strand breaks, and ultimately, apoptosis of the cell. 15 Other mechanisms of 167 
induction of apoptosis by DOXO have been suggested, as well, including inhibition of DNA 168 
and RNA synthesis and formation of free radicals or formaldehyde-mediated DOXO-DNA 169 
adducts. 16 Nonetheless, regardless of the mechanism of action of DOXO within the small 170 
intestinal epithelium, our data demonstrate that DOXO induces apoptosis independent of the 171 
presence of enteric bacteria. What is unclear are the events that occur after the initial 172 
induction of apoptosis, which culminate in crypt loss, villus shrinking, crypt hyperplasia, and 173 
subsequent restitution of normal small intestinal mucosa, and moreover, what specific roles 174 
enteric bacteria play in this damage and repair process. 175 
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 One possibility is that DOXO treatment elicits a direct effect upon intestinal bacteria, 176 
causing a rapid dysbiosis which, in turn, causes direct damage to the intestinal epithelium, 177 
as has been shown for methotrexate. 17  A similar theory has been put forth for the role of 178 
dysbiosis in susceptibility for inflammatory bowel disease. 18,19  Though it is used in human 179 
medicine primarily for its antineoplastic properties, DOXO is a natural anthracycline antibiotic 180 
product of Streptomyces peucetius var. casieus. 20 Since DOXO targets rapidly dividing cells, 181 
and bacteria tend to replicate frequently, bacteria may, indeed, be potential primary targets. 182 
Interestingly, studies suggest that unconjugated DOXO may be available to small intestinal 183 
enteric bacteria within a few hours after dosing. 21 These studies were performed on isolated 184 
perfused rat liver, and showed that approximately 30% of a dose of DOXO (equivalent to a 185 
20 mg/kg intravenous dose) was excreted from isolated liver as unconjugated DOXO into bile 186 
within 3 h of dosing. 21 However, in vitro studies indicate that DOXO has little direct impact 187 
on bacterial growth. These prior findings provide no evidence that DOXO induces a dysbiosis 188 
of the enteric bacterial census, however they do not inform about potential effects on specific 189 
bacteria. Also, our findings do not rule out the possibility that dysbiosis occurs following 190 
DOXO-induced damage by an indirect, but DOXO-dependent, mechanism. Other 191 
chemotherapeutic drugs have been shown to be reactivated by microbial β-glucuronidases, 192 
leading to direct toxicity to mucosal cells. 22,23,24 Therefore, further studies to evaluate 193 
microbial-dependent mucositis following DOXO treatment are underway.     194 
 Another potential mechanism of enteric bacteria-mediated intestinal damage following 195 
DOXO treatment is disruption of the physical barrier that separates the intestinal epithelium 196 
from luminal bacteria. In healthy intestine under homeostatic conditions, a barrier of mucin 197 
serves to minimize the direct contact of luminal bacteria with the mucosa. 25 In addition, 198 
Paneth cells secrete a cadre of antimicrobial factors including: a-defensins, aPLA2, and 199 
lysozyme. 26 However, DOXO-may alter barrier function, permitting an increase in the direct 200 
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association of bacteria with the epithelium, followed by initiation of a bacteria-dependent 201 
signaling cascade via TLR or NOD receptors. An absence of bacteria, therefore, would fail to 202 
trigger this cascade. Of note, Nigro et al. demonstrated an increase in DOXO-induced 203 
apoptosis and dampened repair in Nod2 knock out mice suggesting that the presence of 204 
bacterial products such as muramyl-dipeptide (MDP) might be protective during damage. 27 205 
However, because Nod2 was knocked out in the entire mouse it is not clear whether the 206 
protective effect came from Nod2 signaling within intestinal epithelium or lamina propria-207 
derived cells. Other pro-mucositis chemotherapeutic agents, such as irinotecan, have been 208 
shown to impact mucin secretion, 28 and closer association of microbes with mucosa offers 209 
increased opportunities for activation of TLR and/or NODs on or within epithelial cells and 210 
immune cells intimately associated with the epithelial barrier. 29,30 Likewise, our previous 211 
studies demonstrate alteration in secretory cell allocation within the intestinal crypt, resulting 212 
in increased intermediate cell (both muc2 and lysozyme positive) number which may alter the 213 
mucin barrier. 2,3 This finding is echoed by the increase in muc2+/lysozyme+ cells observed 214 
in crypts of CONV mice at five days after DOXO in the current study. The fact that increases 215 
in muc2+/lysozyme+ cells were not observed in GF mice after DOXO treatment may reflect 216 
an absence of damage and regenerative response or indicate that the alterations in lineage 217 
allocation that follow DOXO result from an increased interaction between enteric bacteria and 218 
epithelium.  219 
      Alternatively, DOXO-driven disruption of the mucosal barrier may not increase the 220 
association between bacteria and epithelia, but instead allow direct penetration of bacteria or 221 
bacterial products through a more permeable epithelium and into the lamina propria, 222 
facilitating direct interaction with resident leukocytes. Sun et al. demonstrated an increase in 223 
epithelial permeability of rat small intestinal epithelium following treatment with DOXO. 31 This 224 
increase allowed particles as large as albumin to move from the intestinal lumen to the lamina 225 
10 
 
propria, suggesting that an increase in permeability following DOXO may allow bacteria 226 
and/or bacterial products to penetrate the IEC barrier. DOXO treatment may also result in an 227 
inflammatory response following penetration of the epithelial barrier by bacterial products, or 228 
via another distinct pathway, such as the AKT-dependent inflammation that leads to 229 
cardiomyopathy following DOXO, or the CCL2-dependent inflammation that leads to renal 230 
fibrosis following DOXO. 32,33 To elucidate these mechanisms, future investigations will 231 
evaluate epithelial permeability, as well as the role of the inflammatory response, following 232 
DOXO. We hypothesize that treatment with DOXO causes an increase in the permeability of 233 
the epithelial barrier (due to a transient induction of increased apoptosis), concomitant with 234 
increased association of enteric bacteria with the mucosa, allowing bacterial products to 235 
penetrate and induce an inflammatory response, resulting in the significant mucosal damage 236 
(and repair) observed in our studies.  237 
 The findings of the current study demonstrate that DOXO-induced apoptosis in small 238 
intestinal crypts occurs independent of the presence of bacteria while mucosal damage after 239 
DOXO is dependent upon the presence of bacteria. These findings have translational 240 
implications supporting that manipulation of the intestinal microbiota during DOXO-based 241 
chemotherapy may reduce damage to the intestinal mucosa. This could allow more effective 242 
anticancer therapies with fewer adverse effects  243 
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Materials and Methods 244 
Animals. Conventionally raised (CONV) adult female C57BL/6 mice were purchased from 245 
Jackson Laboratories and used between 8-10 weeks of age.  Adult female C57BL/6 mice 246 
were raised under germ free (GF) conditions in the National Gnotobiotic Research Center at 247 
the University of North Carolina at Chapel Hill.  Experimental procedures were approved by 248 
the Institutional Animal Care and Use Committee of The University of North Carolina at 249 
Chapel Hill.  Mice were given a single intraperitoneal (IP) injection of DOXO (Pharmacia & 250 
Upjohn Co.) at a dose of 20 mg/kg body weight.  We have previously reported that this dose 251 
induces a reproducible sequela of intestinal damage in mice. 2  Animals were killed at 6 (n=3 252 
for CONV, n=3 for GF), 72 (n=3, n=3), or 120 h (n=3, n=2) after DOXO treatment and 253 
compared with no treatment controls (n=3, n=6).  Small intestine was flushed with ice-cold 254 
phosphate buffered saline (pH 7.4) and a piece of middle jejunum was fixed in 10% buffered 255 
formalin and embedded in paraffin.   256 
Histology.  Formalin-fixed paraffin embedded specimens were oriented to provide sections 257 
perpendicular to the long axis of the bowel, and 5μm sections were used for evaluating 258 
general morphology.  Longitudinal sections of crypts or villi were selected for scoring on the 259 
basis that a single, continuous layer of epithelium followed from crypt base to villus base and 260 
from the crypt-villus junction to the villus tip, respectively.  For scoring cell position, each crypt 261 
was divided in half and cells were numbered sequentially from crypt base to crypt-villus 262 
junction, with cell position “one” being occupied by the first cell at the base of each half crypt, 263 
as previously described. 2  Apoptosis was scored by H&E staining based on the presence of 264 
one or more pyknotic bodies at a given cell position and confirmed by immunoflorescence for 265 
cleaved caspase 3 (CC3). 34  Number of cells in G2-M phase per crypt was assessed by 266 
immunohistochemistry for phosphohistone H3 (pHH3) and counting the number of pHH3 267 
positive cells per crypt.  To directly quantify mitosis, the number of mitotic figures per crypt 268 
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was counted.  Crypt density for each animal was calculated by averaging the number of crypts 269 
contained within five-500 µm lengths of mucosa. Villus height and crypt depth were measured 270 
using Axio Imager software on images captured using an Axio Imager A1 microscope and an 271 
AxioCam MRC 5 high-resolution camera (Carl Zeiss Microimaging, Inc.).  272 
Immunostaining.  For immunohistochemistry, slides were deparaffinized, rehydrated, and 273 
incubated in 3% hydrogen peroxide for 15 min at room temperature (RT) to quench 274 
endogenous peroxidase activity.  Sections were treated to heat-induce epitope retrieval 275 
(Antigen Unmasking Solution cat. # H-3300, Vector Laboratories) and allowed to cool to RT.  276 
Primary antibody (rabbit anti-phospho histone H3 cat. 9701S Cell Signaling Technology) was 277 
applied to each section at 1:300 dilution and incubated for 1h at RT. Sections were then 278 
washed and incubated with biotinylated goat anti-rabbit secondary antibody for 30-60 min at 279 
RT.  After washing, slides were incubated in Vectastain ABC reagent (PK-4000, Vector 280 
Laboratories) for 30 min and then developed in a DAB substrate solution. Quantification of 281 
pHH3+ cells was performed on 25-30 crypts. Data are expressed as number of positive cells 282 
per crypt. For immunofluorescence, slides were deparaffinized, rehydrated, treated to antigen 283 
retrieval in 10mM sodium citrate (pH 6.0) with 0.05% Tween 20 for 30 min, and allowed to 284 
come to RT. Sections were washed and incubated with primary antibodies as previously 285 
reported. 3  Primary antibodies used were as follows: anti-lysozyme (sc-27958, Santa Cruz 286 
Biotechnology, 1:100 dilution), anti-mucin2 (Muc2; sc-15334, Santa Cruz Biotechnology, 287 
1:200 dilution), and anti-active caspase 3 (cat. no. 9661, Cell Signaling Technology, 1:200 288 
dilution). Sections were washed and incubated with corresponding fluorescently conjugated 289 
secondary antibodies. Finally, sections were mounted using Vectashield Mounting Medium 290 
with DAPI (H-1200 Vector Laboratories) and evaluated using an Axio Imager A1 microscope 291 
and an AxioCam MRC 5 high resolution camera.  292 
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Statistics. All quantitative results are presented as mean ± standard error (SE). All data were 293 
subjected to one-way ANOVA with correction for multiple comparisons using the Fisher’s 294 
procedure.  For all comparisons, a P value of ≤ 0.05 was considered significant.  295 
14 
 
Acknowledgments  296 
This work was facilitated by services from the Cell Services and Histology Core of the Center 297 
for Gastrointestinal Biology and Disease (National Institutes of Diabetes and Digestive and 298 
Kidney Disease Grant P30 DK34987). Immunohistological services provided by the Histology 299 
Research Core Facility in the Department of Cell Biology and Physiology at the University of 300 
North Carolina, Chapel Hill NC. Work was supported by grant R01 DK100508 (C.M.D.) and 301 
the Department of Surgery at the University of North Carolina at Chapel Hill.   302 
15 
 
Figure Legends 303 
 304 
Figure1. DOXO induces apoptosis in intestinal epithelium irrespective of the presence of 305 
enteric bacteria. A. H&E images demonstrating mitotic bodies and immunofluorescence 306 
staining indicating the presence of active caspase 3-positive cells (green) 6h following DOXO 307 
treatment in both CONV and GF mice. Arrows indicated apoptotic cells. B. Quantitation of 308 
the number of apoptotic cells per crypt, for a total of 20 crypts per animal, in CONV and GF 309 
jejunal tissue from control mice and 6, 72, and 120h after DOXO treatment. * indicates values 310 
significantly different from their respective 0h controls p≤0.05. C. Positional analysis of 311 
apoptotic bodies in jejunal epithelium from CONV and GF mice 6h following DOXO treatment. 312 
Scale bar: 30 µm. 313 
 314 
Figure 2. DOXO treatment does not alter crypt depth or villus height in GF mice. A. 315 
Micrographs of representative H&E stained sections from GF and CONV mice of control 316 
tissue and 6, 72 and 120h following DOXO treatment. B. Quantitation of crypt depth on 10-317 
15 crypts/villi in CONV and GF jejunal tissue from control mice and 6, 72, and 120h after 318 
DOXO treatment. * indicates values significantly different from their respective controls 319 
p≤0.05. # indicates values significantly different within a particular time point p≤0.05. C. 320 
Quantitation of villus height in CONV and GF jejunal tissue from control mice and 6, 72, and 321 
120h after DOXO treatment. Scale bar: 50 µm. 322 
 323 
Figure 3. DOXO treatment does not impact proliferation or mitotic index in jejunal epithelium 324 
of GF mice. A. Micrograph showing representative staining for pHH3 on jejunal sections from 325 
GF and CONV mice. B. Quantitation of pHH3+ cells in CONV and GF jejunal tissue from 326 
control mice and 6, 72, and 120h after DOXO treatment. * indicates values significantly 327 
different from their respective controls p≤0.05. # indicates values significantly different within 328 
a particular time point p≤0.05. C. Quantitation of mitotic index in CONV and GF jejunal tissue 329 
from control mice and 6, 72, and 120h after DOXO treatment. # indicates values significantly 330 




Figure 4. DOXO treatment does not alter crypt density in jejunal mucosa of GF mice. * 333 
indicates values significantly different from their respective controls p≤0.05. # indicates 334 
values significantly different within a particular time point p≤0.05.  335 
 336 
Figure 5. Expansion of the Paneth cell compartment and allocation of intermediate cells are 337 
not observed in GF mice following DOXO. Immunofluorescent detection of lysozyme (red), 338 
muc2 (green), and nuclei (blue) in jejunal sections from GF and CONV mice. Arrows indicate 339 
‘intermediate cells’, characterized by their co-expression of lysozyme (red) and muc2 (green). 340 
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